Medexus Pharmaceuticals Second Quarter 2025 Earnings: EPS: US$0.004 (vs US$0.053 loss in 2Q 2024)

Medexus Pharmaceuticals (TSE:MDP) Second Quarter 2025 Results

Key Financial Results

• Revenue: US$26.3m (down 13% from 2Q 2024).
• Net income: US$110.0k (up from US$1.09m loss in 2Q 2024).
• Profit margin: 0.4% (up from net loss in 2Q 2024).
• EPS: US$0.004 (up from US$0.053 loss in 2Q 2024).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Medexus Pharmaceuticals Earnings Insights

Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada.

Performance of the Canadian Pharmaceuticals industry.

The company's shares are down 11% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Medexus Pharmaceuticals has 5 warning signs (and 2 which are concerning) we think you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.